LNC
40
-2
SRE
68
2
PNR
30
-2
AMT
39
3
CMG
41
3
DG
57
7
PNW
69
2
ECL
59
-3
JCI
51
-3
RF
61
3
PH
60
-2
FIS
48
2
AES
46
2
CSCO
57
3
NDAQ
57
2
LB
55
7
EOG
62
6
YUM
58
2
UNP
50
2
GLW
82
3
LNC
40
-2
SRE
68
2
PNR
30
-2
AMT
39
3
CMG
41
3
DG
57
7
PNW
69
2
ECL
59
-3
JCI
51
-3
RF
61
3
PH
60
-2
FIS
48
2
AES
46
2
CSCO
57
3
NDAQ
57
2
LB
55
7
EOG
62
6
YUM
58
2
UNP
50
2
GLW
82
3
Financhill
Back

Astellas Pharma, Inc. 10K Form

Buy
60

ALPMY
Astellas Pharma, Inc.

Last Price:
$16.48
Seasonality Move:
3.56%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive ALPMY News And Ratings

See the #1 stock for the next 7 days that we like better than ALPMY

ALPMY Financial Statistics

Sales & Book Value

Annual Sales: $12.5B
Cash Flow: $371M
Price / Cash Flow: 11.21
Annual Sales: $6.28
Price / Book: 2.58

Profitability

EPS (TTM): 1.19880
Net Income (TTM): $2.2B
Gross Margin: $9.4B
Return on Equity: 20.68%
Return on Assets: 9.47%

Astellas Pharma, Inc. Earnings Forecast

Key Astellas Pharma, Inc. Financial Ratios

  • The Gross Profit Margin over the past 37 years for ALPMY is 74.59%.
  • The Selling, General & Administrative Expenses for ALPMY have been equal to 44.08% of Gross Profit Margin.
  • The Research & Development expenses have been 17.13% of Revenue.
  • The Interest Expense is 28.28% of Operating Income.
  • The Net Earning history of ALPMY is 2.65% of Total Revenues.
  • Per Share Earnings over the last 37 years have been positive in 20 years.

Astellas Pharma, Inc. Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: OTCM
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: ALPMY
Website: astellas.com

Debt

Debt-to-Equity Ratio: 0.41
Current Ratio: 1.09
Quick Ratio: 0.78

Price-to-Earnings

Trailing P/E Ratio: 87.39
Forward P/E Ratio: 0

ALPMY Technical Analysis vs Fundamental Analysis

Buy
60
Astellas Pharma, Inc. (ALPMY) is a Buy

Is Astellas Pharma, Inc. a Buy or a Sell?